Grant: Idea to Innovation
Université Laval
$60,250.00
The biomanufacturing of retroviral and lentiviral vectors
EF 2008-09
Résumé
The production of retroviral vectors for large-scale clinical trials is limited due to the adherent nature of the existing packaging cell lines. Furthermore, serum used to supplement media can contribute to introduce biological contaminants like proteins, viruses and prions. Serum is also an expensive raw material and it increases the complexity, duration and cost of downstream processing (purification, concentration and infectious virus recovery). We are proposing to generate retroviral but also lentiviral packaging cell lines that could grow in suspension and serum-free media (SFM). Cells with such properties could allow the biomanufacturing of vectors in bioreactors with practically no size limit.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
355124-2007
Name nom
Caruso, Manuel
Department département
Biologie médicale
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2007
Award amount
60250
Program id
I2IPJ
Program nane en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
2
Nb partie
2
Application title
The biomanufacturing of retroviral and lentiviral vectors
Keyword
NA
Application summary
The production of retroviral vectors for large-scale clinical trials is limited due to the adherent nature of the existing packaging cell lines. Furthermore, serum used to supplement media can contribute to introduce biological contaminants like proteins, viruses and prions. Serum is also an expensive raw material and it increases the complexity, duration and cost of downstream processing (purification, concentration and infectious virus recovery). We are proposing to generate retroviral but also lentiviral packaging cell lines that could grow in suspension and serum-free media (SFM). Cells with such properties could allow the biomanufacturing of vectors in bioreactors with practically no size limit.